The Office of the Assistant Secretary for Preparedness and Response recently e-mailed important updates to expand the eligibility criteria for two monoclonal antibody therapies—bamlanivimab and etesevimab administered together—and the combination therapy casirivimab/imdevimab. According to the Food and Drug Administration’s emergency use authorization, both therapies are used to treat mild to moderate COVID-19 in patients at high risk of progressing to severe COVID-19 and/or hospitalization.
The FDA’s updates expand the definition of high-risk patients by:
- eliminating specific thresholds for defining older age
- removing specific body mass index thresholds in defining overweight and obese individuals
- not limiting the definition of high risk to specific medical conditions and factors